Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Uyttenhove, Catherine, Pilotte, Luc, Théate, Ivan, Stroobant, Vincent, Colau, Didier, Parmentier, Nicolas, Boon, Thierry, Van den Eynde, Benoît J·2003·Nature Medicine

DOI 10.1038/nm934

Cited by (1,003)

Items 201–300 of 1,003

Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase
F. Forouhar, J. L. Ross Anderson, Christopher G. Mowat, Sergey M. Vorobiev, Arif Hussain, Mariam Abashidze, Chiara Bruckmann, Sarah J. Thackray, J. Seetharaman, Todd Tucker et al. · 2006 · Proceedings of the National Academy of Sciences
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Zhengyi Wang, Xiaoying Wu · 2020 · Cancer Medicine
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia
Valentina Audrito, Sara Serra, Davide Brusa, Francesca Mazzola, Francesca Arruga, Tiziana Vaisitti, Marta Coscia, Rossana Maffei, Davide Rossi, Tao Wang et al. · 2014 · Blood
Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment
Weifang Ling, Jimin Zhang, Zengrong Yuan, Guangwen Ren, Liying Zhang, Xiao‐Dong Chen, Arnold B. Rabson, Arthur I. Roberts, Ying Wang, Yufang Shi · 2014 · Cancer Research
Targeting amino acid metabolism in cancer growth and anti-tumor immune response
Elitsa Antonova Ananieva · 2015 · World Journal of Biological Chemistry
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive ‘Cold’ Tumors ‘Hot’
George C. Prendergast, Arpita Mondal, Souvik Dey, Lisa D. Laury‐Kleintop, Alexander J. Muller · 2017 · Trends in cancer
Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients
Georg Weinlich, Christian Murr, Laura Richardsen, Christiana Winkler, Dietmar Fuchs · 2006 · Dermatology
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity
Tracy L. McGaha, Lei Huang, Henrique de Paula Lemos, Richard A. Metz, Mario R. Mautino, George C. Prendergast, Andrew L. Mellor · 2012 · Immunological Reviews
Opposing Roles of Type I Interferons in Cancer Immunity
Giselle M. Boukhaled, Shane M. Harding, David G. Brooks · 2020 · Annual Review of Pathology Mechanisms of Disease
Role of the immunosuppressive microenvironment in immunotherapy
Garth W. Tormoen, Marka R. Crittenden, Michael J. Gough · 2018 · Advances in Radiation Oncology
Tumor Abnormality-Oriented Nanomedicine Design
Quan Zhou, Jiajia Xiang, Nasha Qiu, Yechun Wang, Ying Piao, Shiqun Shao, Jianbin Tang, Zhuxian Zhou, Youqing Shen · 2023 · Chemical Reviews
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
Partha Sarathi Chowdhury, Kenji Chamoto, Tasuku Honjo · 2017 · Journal of Internal Medicine
Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells
Laia Gorchs, Carlos Fernández Moro, Peter Bankhead, Katharina P. Kern, Imrul Sadeak, Qingda Meng, Elena B. Rangelova, Helen Kaipe · 2019 · Frontiers in Immunology
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
Yichao Chen, Rui Xia, Yixian Huang, Wenchen Zhao, Jiang Li, Xiaolan Zhang, Pengcheng Wang, Raman Venkataramanan, Jie Fan, Wen Xie et al. · 2016 · Nature Communications
Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response
Shamir Cassim, Jacques Pouysségur · 2019 · International Journal of Molecular Sciences
Role of the tumor microenvironment in pancreatic cancer
Takashi Murakami, Yukihiko Hiroshima, Ryusei Matsuyama, Yuki Homma, Robert M. Hoffman, Itaru Endo · 2019 · Annals of Gastroenterological Surgery
Trial watch: IDO inhibitors in cancer therapy
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli · 2020 · OncoImmunology
Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice
Shuangshuang Yang, Xishuai Li, Fangfang Hu, Yinlong Li, Yunyun Yang, Junkai Yan, Chunxiang Kuang, Qing Yang · 2013 · Journal of Medicinal Chemistry
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
Takefumi Komiya, Chao Hui Huang · 2018 · Frontiers in Oncology
Critical Neurotransmitters in the Neuroimmune Network
Thomas Hodo, Maria Teresa P. de Aquino, Akiko Shimamoto, Anil Shanker · 2020 · Frontiers in Immunology
The immunopeptidomic landscape of ovarian carcinomas
Heiko Schuster, Janet K. Peper-Gabriel, Hans-Christian Bösmüller, Kevin Roehle, Linus Backert, Tatjana Bilich, Britta Ney, Markus W. Loeffler, Daniel Johannes Kowalewski, Nico Trautwein et al. · 2017 · Proceedings of the National Academy of Sciences
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
Murrium Ahmad, RobertC. Rees, SelmanA. Ali · 2004 · Cancer Immunology Immunotherapy
Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
Eduard Dolušić, Pierre Larrieu, Laurence Moineaux, Vincent Stroobant, Luc Pilotte, Didier Colau, Lionel Pochet, Benoit J. Van den Eynde, Bernard Masereel, Johan Wouters et al. · 2011 · Journal of Medicinal Chemistry
Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles
Jing Li, Yu Luo, Ziling Zeng, Dong Mei Cui, Jiaguo Huang, Chenjie Xu, Liping Li, Kanyi Pu, Ruiping Zhang · 2022 · Nature Communications
Indoleamine 2,3-Dioxygenase
Hatem Hussein Soliman, Melanie Mediavilla-Varela, Scott Joseph Antonia · 2010 · The Cancer Journal
Structure−Activity Study of Brassinin Derivatives as Indoleamine 2,3-Dioxygenase Inhibitors
Paul M. Gaspari, Tinku Banerjee, William P. Malachowski, Alexander J. Muller, George C. Prendergast, James B. DuHadaway, Shauna M. Bennett, Ashley M. Donovan · 2005 · Journal of Medicinal Chemistry
Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells
Mario Ricciardi, Marco Zanotto, Giorgio Malpeli, G. Bassi, Omar Perbellini, Marco Chilosi, Francesco Bifari, Mauro Krampera · 2015 · British Journal of Cancer
Role of Innate Immunity against Human Papillomavirus (HPV) Infections and Effect of Adjuvants in Promoting Specific Immune Response
Alfredo Amador-Molina, José Hernández-Valencia, Edmundo Lamoyi, Adriana Contreras‐Paredes, Marcela Lizano · 2013 · Viruses
Tryptophan-Catabolizing Enzymes – Party of Three
Helen J. Ball, Felicita Fedelis Jusof, Supun M. Bakmiwewa, Nicholas Henry Hunt, Hajime Julie Yuasa · 2014 · Frontiers in Immunology
Kynurenine Pathway Enzymes in Dendritic Cells Initiate Tolerogenesis in the Absence of Functional IDO
Maria Laura Belladonna, Ursula Grohmann, Paolo Guidetti, Claudia Volpi, Roberta Bianchi, Maria C. Fioretti, Robert M. Schwarcz, Francesca Fallarino, Paolo Puccetti · 2006 · The Journal of Immunology
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival
Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, MATTHEW D. GENET, Galina Gritsina, Balázs Győrffy, Priscilla Kaliopi Brastianos, David C. Binder, Jeffrey Alan Sosman et al. · 2017 · Clinical Cancer Research
Updates on immunotherapy for colorectal cancer
Aparna Kalyan, Sheetal Mehta Kircher, Hiral Anil Shah, Mary F. Mulcahy, Al B. Benson · 2018 · Journal of Gastrointestinal Oncology
Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression
Minhee Kim, Jong Sam Lee, Woo-Yeon Kim, Jong Hun Lee, Bong‐Hyun Jun, Keun‐Sik Kim, Dong‐Eun Kim · 2022 · Journal of Controlled Release
Interferon-γ–triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells
Jürgens, Birgit, Hainz, Ursula, Fuchs, Dietmar, Felzmann, Thomas, Heitger, Andreas · 2009 · Blood
Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation
David H. Munn · 2006 · Current Opinion in Immunology
Recent synthetic and medicinal perspectives of tryptanthrin
Ramandeep Kaur, Sundeep Kaur Manjal, Ravindra Kumar Rawal, Kapil Kumar · 2017 · Bioorganic & Medicinal Chemistry
Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+CD25+ Foxp3+ T Regulatory Cells
Manuela Brenk, Marina Scheler, Susanne Koch, Jürgen Neumann, Osamu Takikawa, Georg Alexander Häcker, Thomas R.M. Bieber, Dagmar von Bubnoff · 2009 · The Journal of Immunology
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
Van den Eynde, Benoit J., van Baren, Nicolas, Baurain, Jean-François · 2020 · Annual Review of Cancer Biology
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Derya Kabacaoğlu, Katrin J. Ciecielski, Dietrich Alexander Ruess, Hana Algül · 2018 · Frontiers in Immunology
Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling
Alessandra Fiore, Leonie Zeitler, Marion Russier, Annette Groß, Maria-Kathrin Hiller, Joanne L. Parker, Luca J. Stier, Thomas Köcher, Simon L. Newstead, Peter J. Murray · 2022 · Molecular Cell
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Soliman, Hatem H., Jackson, Erica, Neuger, Tony, Dees, E. Claire, Harvey, R. Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N., Link, Charles et al. · 2014 · Oncotarget
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Laurence P. Diggs, Eddy C. Hsueh · 2017 · Biomarker Research
Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery
Javed Khan, F. Forouhar, Xiao Tao, Liang Tong · 2007 · Expert Opinion on Therapeutic Targets
The Kynurenine Pathway is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy
Jean‐Pierre Routy, Bertrand Routy, Gina M. Graziani, Vikram Mehraj · 2016 · International Journal of Tryptophan Research
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
Marc Hennequart, Luc Pilotte, Stefania Canè, Delia Hoffmann, Vincent Stroobant, Etienne De Plaen, Benoit J. Van den Eynde · 2017 · Cancer Immunology Research
Evolving immunosuppressive microenvironment during human cervical carcinogenesis
Akiko Kobayashi, VIVIAN K. WEINBERG, Teresa M. Darragh, Karen Smith‐McCune · 2008 · Mucosal Immunology
Oncogene-Directed Alterations in Cancer Cell Metabolism
Nagarajan, Arvindhan, Malvi, Parmanand, Wajapeyee, Narendra · 2016 · Trends in Cancer
Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition
Ute F. Röhrig, Somi Reddy Majjigapu, Aurélien Grosdidier, Sylvian Bron, Vincent Stroobant, Luc Pilotte, Didier Colau, Pierre Vogel, Benoit J. Van den Eynde, Vincent Zoete et al. · 2012 · Journal of Medicinal Chemistry
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
Ke Pan, Hui Wang, Min-Shan Chen, Hua-kun Zhang, Desheng Weng, Jun Zhou, Wei Chieh Huang, Xiao Hai Li, Hai-feng Song, Jian‐Chuan Xia · 2008 · Journal of Cancer Research and Clinical Oncology
Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma
Rainer Riesenberg, Christoph Weiler, Oliver Spring, Martin Eder, Alexander Büchner, Tanja Popp, Mirna Castro, Robert Kammerer, Osamu Takikawa, Rudolf Alexander Hatz et al. · 2007 · Clinical Cancer Research
Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine
Shuji Ogino, Jonathan Andrew Nowak, Tsuyoshi Hamada, Amanda I. Phipps, Ulrike Peters, Danny A. Milner, Edward L. Giovannucci, Reiko Nishihara, Marios Giannakis, Wendy S. Garrett et al. · 2018 · Gut
Systemic application of CpG‐rich DNA suppresses adaptive T cell immunity via induction of IDO
Gerhard Wingender, Natalio Garbi, Beatrix Schumak, Frank Jüngerkes, Elmar Endl, Dagmar von Bubnoff, Julia Steitz, Jörg Striegler, Gerd Moldenhauer, Thomas Tüting et al. · 2005 · European Journal of Immunology
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER−/PR−/Her2− Human Breast Cancer Cells
Novikov, Olga, Wang, Zhongyan, Stanford, Elizabeth A., Parks, Ashley J., Ramirez-Cardenas, Alejandra, Landesman, Esther, Laklouk, Israa, Sarita-Reyes, Carmen, Gusenleitner, Daniel, Li, Amy et al. · 2016 · Molecular Pharmacology
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Stefan Löb, Alfred Königsrainer, Richard Schäfer, Hans‐Georg Rammensee, Gerhard Opelz, Peter Terness · 2007 · Blood
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
Powell Perng, Michael K. Lim · 2015 · Frontiers in Oncology
RNA Interference and Cancer Therapy
Zhaohui Wang, Donald D. Rao, Neil N. Senzer, John J. Nemunaitis · 2011 · Pharmaceutical Research
Spatial proteomics identifies JAKi as treatment for a lethal skin disease
Thierry M. Nordmann, Holly Anderton, Akito Hasegawa, Lisa Schweizer, Peng Zhang, Pia‐Charlotte Stadler, Ankit Sinha, Andreas Metousis, Florian A. Rosenberger, Maximilian Zwiebel et al. · 2024 · Nature
Expression of indoleamine 2, 3‐dioxygenase and the recruitment of Foxp3‐expressing regulatory T cells in the development and progression of uterine cervical cancer
Takafumi Nakamura, Tomoko Shima, Ai Saeki, 隆雄日高, Akitoshi Nakashima, Osamu Takikawa, Shigeru Saito · 2007 · Cancer Science
A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy
Samuel G. Awuah, Yao‐Rong Zheng, Peter M. Bruno, Michael T. Hemann, Stephen J. Lippard · 2015 · Journal of the American Chemical Society
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer
Ruth J. Davis, Carter Van Waes, Clint Tanner Allen · 2016 · Oral Oncology
DC subsets in positive and negative regulation of immunity
Caroline Coquerelle, Muriel Moser · 2010 · Immunological Reviews
Tryptophan metabolism: entering the field of aging and age-related pathologies
Annemieke T. van der Goot, Ellen A. A. Nollen · 2013 · Trends in Molecular Medicine
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, William Jay Ramsey, Eugene Paul Kennedy, Mario R. Mautino, Charles J. Link et al. · 2018 · Journal for ImmunoTherapy of Cancer
Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors
Ute F. Röhrig, Loay Awad, Aurélien Grosdidier, Pierre Larrieu, Vincent Stroobant, Didier Colau, Vincenzo Cerundolo, Andrew J.G. Simpson, Pierre Vogel, Benoit J. Van den Eynde et al. · 2010 · Journal of Medicinal Chemistry
Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease
Amos A. Fatokun, Nicholas Henry Hunt, Helen J. Ball · 2013 · Amino Acids
TLR8 signaling enhances tumor immunity by preventing tumor‐induced T‐cell senescence
Ye, Jian, Ma, Chunling, Hsueh, Eddy C, Dou, Jie, Mo, Wei, Liu, Shuai, Han, Bing, Huang, Yi, Zhang, Yanping, Varvares, Mark A et al. · 2014 · EMBO Molecular Medicine
Eosinophil Granulocytes Account for Indoleamine 2,3-Dioxygenase-Mediated Immune Escape in Human Non Small Cell Lung Cancer
Simonetta Astigiano, Barbara Morandi, Roberta Costa, Luca Mastracci, Antonella D'Agostino, Giovanni Battista Ratto, Giovanni Melioli, Guido Frumento · 2005 · Neoplasia
Neopterin, a prognostic marker in human malignancies
Robert Sucher, Katharina Schroecksnadel, Günter Weiß, Raimund Margreiter, Dietmar Fuchs, Gerald Brandacher · 2009 · Cancer Letters
IDO1: An important immunotherapy target in cancer treatment
Fangxuan Li, Rupeng Zhang, Shixia Li, Juntian Liu · 2017 · International Immunopharmacology
Nitrogen Metabolism in Cancer and Immunity
Kiran Kurmi, Marcia C. Haigis · 2020 · Trends in Cell Biology
Advances in immunotherapy for melanoma
Jason Mark Redman, Geoffrey Thomas Gibney, Michael B. Atkins · 2016 · BMC Medicine
Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Adelphe M. Mfuh, Oleg V. Larionov · 2015 · Current Medicinal Chemistry
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease
Anna Maria Wolf, Dominik Georg Friedrich Wolf, Holger F. Rumpold, Alexander Rupert Moschen, Arthur Kaser, Peter Obrist, Dietmar Fuchs, Gerald Brandacher, Christiane Winkler, Karel J. Geboes et al. · 2004 · Clinical Immunology
Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFα and NO-dependent mechanism, promoting a tumor-supportive environment
Michaeli, Janna, Shaul, Merav E., Mishalian, Inbal, Hovav, Avi-Hai, Levy, Liran, Zolotriov, Lidia, Granot, Zvi, Fridlender, Zvi G. · 2017 · OncoImmunology
NAD<sup>+</sup>metabolism and oxidative stress: the golden nucleotide on a crown of thorns
Massudi, Hassina, Grant, Ross, Guillemin, Gilles J, Braidy, Nady · 2012 · Redox Report
Heme oxygenase‐1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3‐dioxygenase
Marcelo Hill, Victoria Pereira, Christine Chauveau, Rachid Zagani, Séverine Remy, Laurent Tesson, Daniel Mazal, Luis Ubillos, Régis Brion, Kashif Ashgar et al. · 2005 · The FASEB Journal
Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages
Qiyi Zhao, Dong‐Ming Kuang, Yan Wu, Christos Xiao, Xuefeng Li, Tuan-Jie Li, Limin Zheng · 2011 · The Journal of Immunology
Circadian rhythms and cancers: the intrinsic links and therapeutic potentials
Li Zhou, Zhe Zhang, Edouard Collins Nice, Canhua Huang, Wei Zhang, Yong Cheng Tang · 2022 · Journal of Hematology & Oncology
The Kynurenine Pathway in Brain Tumor Pathogenesis
Seray Adams, Nady Braidy, Alban Bessesde, Bruce James Brew, Ross Grant, Charlie Teo, Gilles J. Guillemin · 2012 · Cancer Research
Differences in Gastric Carcinoma Microenvironment Stratify According to EBV Infection Intensity: Implications for Possible Immune Adjuvant Therapy
Michael J. Strong, Guorong Xu, Joseph Coco, Carl Baribault, Dass S. Vinay, Michelle R. Lacey, Amy L. Strong, Teresa A. Lehman, Michael B. Seddon, Zhen Nan Lin et al. · 2013 · PLoS Pathogens
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer
Didem Saka, Muazzez Gökalp, Betül Piyade, Nedim Can Çevik, Elif Arik Sever, Derya Unutmaz, Guralp Onur Ceyhan, İhsan Ekin Demir, Hande Asimgil · 2020 · Cancers
IDO expression in the brain: a double-edged sword
Erik Kwidzinski, Ingo Bechmann · 2007 · Journal of Molecular Medicine
Improving cancer immunotherapy by targeting tumor-induced immune suppression
Trina J. Stewart, Mark John Smyth · 2011 · Cancer and Metastasis Reviews
Comparison of Amino Acid Positron Emission Tomographic Radiotracers for Molecular Imaging of Primary and Metastatic Brain Tumors
Csaba Juhász, Shalini Dwivedi, David Olayinka. Kamson, Sharon K. Michelhaugh, Sandeep Mittal · 2014 · Molecular Imaging
Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection
Agnes Witkiewicz, Timothy Keith Williams, Joseph A. Cozzitorto, Brandice Durkan, Shayna L. Showalter, Charles J. Yeo, Jonathan Robert Brody · 2008 · Journal of the American College of Surgeons
New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site
Victor Appay, Camilla Jandus, Verena Voelter, Séverine Reynard, Sarah E. Coupland, Donata Rimoldi, Danielle Líénard, Philippe Guillaume, Arthur Μ. Krieg, Jean‐Charles Cerottini et al. · 2006 · The Journal of Immunology
Metabolic challenges and interventions in CAR T cell therapy
Jhan-Jie Peng, Limei Wang, Zhiyu Li, Cheng‐Lung Ku, Ping‐Chih Ho · 2023 · Science Immunology
Exercise as adjunct therapy in cancer
Ashcraft, Kathleen A., Warner, Allison Betof, Jones, Lee W., Dewhirst, Mark W. · 2019 · Seminars in Radiation Oncology
Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
Liesbeth Ferdinande, Christine Decaestecker, Laurine Verset, Anne Mathieu, Xavier Moles Lopez, A-M Negulescu, Tom Van Maerken, Isabelle J. Salmon, Claude A Cuvelier, Pieter Demetter · 2011 · British Journal of Cancer
Indoleamine 2,3 dioxygenase and regulation of T cell immunity
Andrew L. Mellor · 2005 · Biochemical and Biophysical Research Communications
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
Feng Qian, Jeannine Villella, Paul K. Wallace, Paulette Y. Mhawech-Fauceglia, Joseph Dennis Tario, Chris Andrews, Junko Matsuzaki, Danila Valmori, Maha Ayyoub, Peter Jonathan Frederick et al. · 2009 · Cancer Research
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Grazia Carbotti, Gaia Barisione, Irma Airoldi, Delia Mezzanzanica, Marina Bagnoli, Simone Ferrero, Andrea Petretto, Marina Fabbi, Silvano Ferrini · 2015 · Oncotarget
Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes
Marie Solvay, Pauline Pfänder, Simon Klaessens, Luc Pilotte, Vincent Stroobant, Juliette Lamy, Stefan Naulaerts, Quentin Spillier, Raphaël Frédérick, Etienne De Plaen et al. · 2023 · Journal for ImmunoTherapy of Cancer
Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Alexander J. Muller, George C. Prendergast · 2007 · Current Cancer Drug Targets
Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology
Seray Adams, Charles Teo, Kerrie Leanne McDonald, Anna Zinger, Sonia Bustamante, Chai K. Lim, Gayathri Sundaram, Nady Braidy, Bruce James Brew, Gilles J. Guillemin · 2014 · PLoS ONE
Immunotherapy of melanoma
Iwona A. Lugowska, Paweł Teterycz, Piotr Lukasz Rutkowski · 2018 · Współczesna Onkologia
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li, Aaron R. Bolduc, Md Nasrul Hoda, Denise N. Gamble, Sarah-Bianca Dolisca, Anna Bolduc, Kelly Hoang, Claire Ashley, David C. McCall, Amyn M. Rojiani et al. · 2014 · Journal for ImmunoTherapy of Cancer
PGE2-Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells
Nataša Obermajer, Jeffrey L. Wong, Robert P. Edwards, Kunle O. Odunsi, Kirsten B. Moysich, Paweł Kaliński · 2012 · Immunological Investigations
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1 H -indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
Stefano Crosignani, Patrick Bingham, Pauline Bottemanne, Hélène Cannelle, Sandra Cauwenberghs, Marie Cordonnier, Deepak Dalvie, Frederik D. Deroose, Jun Li Feng, Bruno Gomes et al. · 2017 · Journal of Medicinal Chemistry
l-Kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species
Hyunkeun Song, Hyunjin Park, Yeong-Seok Kim, Kwang Dong Kim, Hyun-Kyung Lee, Dae-Ho Cho, Jae-Wook Yang, Dae Young Hur · 2011 · International Immunopharmacology